Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript

Stacy Lindborg: Sure. Daniel, this is an additional technology that we have been developing and certainly have thought of as an interesting and exciting part of our portfolio. And what’s interesting about exosome is, of course, that it allows us to move into and explore different diseases that can carry cargo and can penetrate different parts of human bodies, and therefore brings different advantages. But we’ve done a number of preclinical studies, some of which we’ve published. And we think there’s a lot of excitement in this technology platform, which again offers a wide array of diseases that there’s a great unmet need and that nanoscale particles really would be able to open possible administration options that would be very effective for treatment.

Unidentified Analyst: Excellent. Thank you both so much. I really appreciate it.

Chaim Lebovits: Thank you.

Operator: Thank you very much. That appears to be the end of our question-and-answer session. I will now hand back over to Chaim for closing comments.

Chaim Lebovits: Thank you very much, and have a wonderful day. Thank you.

Operator: Thank you, everybody. This does conclude today’s conference. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.

Chaim Lebovits: Thank you, Jenny.

Operator: Thank you.